A. D. de Boer

发表

Melanocyte lineage-specific antigen gp100 is recognized by melanoma- derived tumor-infiltrating lymphocytes

C. Figdor, S. Rosenberg, G. Adema, 1994, The Journal of experimental medicine.

Biodistribution and vaccine efficiency of murine dendritic cells are dependent on the route of administration.

W. Oyen, C. Figdor, C. Punt, 1999, Cancer research.

Prognostic relevance of plasminogen activators and their inhibitors in colorectal cancer.

C. V. D. van de Velde, S. Ganesh, Cornelis F. M. Sier, 1994, Cancer research.

The cytotoxicity of halothane in isolated hepatocytes: Evidence for two different mechanisms.

B. Blaauboer, A. D. de Boer, A. A. van Iersel, 1988, Toxicology in vitro : an international journal published in association with BIBRA.

Intranodal vaccination with mRNA-optimized dendritic cells in metastatic melanoma patients

C. Figdor, C. Punt, B. Neyns, 2015, Oncoimmunology.

Episialin (MUC1) inhibits cytotoxic lymphocyte-target cell interaction.

C. Melief, C. Figdor, M. Ligtenberg, 1993, Journal of immunology.

Melanocyte lineage-specific antigens recognized by monoclonal antibodies NKI-beteb, HMB-50, and HMB-45 are encoded by a single cDNA.

C. Figdor, D. Ruiter, G. Adema, 1993, The American journal of pathology.

Route of Administration Modulates the Induction of Dendritic Cell Vaccine–Induced Antigen-Specific T Cells in Advanced Melanoma Patients

W. Oyen, C. Figdor, C. Punt, 2011, Clinical Cancer Research.

pMel17 is recognised by monoclonal antibodies NKI-beteb, HMB-45 and HMB-50 and by anti-melanoma CTL.

C. Figdor, G. Adema, P. Hohenstein, 1996, British Journal of Cancer.

Identification of a novel peptide derived from the melanocyte‐specific gp100 antigen as the dominant epitope recognized by an HLA‐A2.1‐restricted anti‐melanoma CTL line

C. Figdor, G. Adema, Y. Kawakami, 1995, International journal of cancer.

Generation of antimelanoma cytotoxic T lymphocytes from healthy donors after presentation of melanoma-associated antigen-derived epitopes by dendritic cells in vitro.

C. Figdor, E. Danen, G. Adema, 1995, Cancer research.

Molecular characterization of the melanocyte lineage-specific antigen gp100.

C. Figdor, G. Adema, W. Loenen, 1994, The Journal of biological chemistry.

Prophylactic vaccines are potent activators of monocyte-derived dendritic cells and drive effective anti-tumor responses in melanoma patients at the cost of toxicity

W. Oyen, C. Figdor, C. Punt, 2016, Cancer Immunology, Immunotherapy.

Both LFA‐1‐positive and ‐deficient T cell clones require the CD2/LFA‐3 interaction for specific cytolytic activation

A. Fischer, C. Melief, C. Figdor, 1992, European journal of immunology.

Adhesion of T and B lymphocytes to extracellular matrix and endothelial cells can be regulated through the beta subunit of VLA

C. Melief, C. Figdor, R. Huijbens, 1992, The Journal of cell biology.

Cloning, expression and tissue distribution of the murine homologue of the melanocyte lineage-specific antigen gp100.

C. Figdor, G. Adema, A. Schmidt, 1997, Melanoma research.

Effective Clinical Responses in Metastatic Melanoma Patients after Vaccination with Primary Myeloid Dendritic Cells

C. Figdor, C. Punt, C. Blank, 2015, Clinical Cancer Research.

Vaccination of colorectal cancer patients with CEA-loaded dendritic cells: antigen-specific T cell responses in DTH skin tests.

C. Figdor, T. Ruers, C. Punt, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Adjuvant dendritic cell vaccination induces tumor-specific immune responses in the majority of stage III melanoma patients

C. Figdor, C. Punt, J. D. de Wilt, 2016, Oncoimmunology.

Development of 111In-labeled tumor-associated antigen peptides for monitoring dendritic-cell-based vaccination.

W. Oyen, C. Figdor, G. Adema, 2006, Nuclear medicine and biology.

Analysis of dendritic cell trafficking using EGFP-transgenic mice.

W. Oyen, C. Figdor, G. Adema, 2003, Immunology letters.

Cloning, expression and tissue distribution of the murine homologue of the melanocyte lineagespecific antigen gp100

C. Figdor, G. Adema, A. Schmidt, 1997 .

Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice.

C. Figdor, C. Punt, J. Kaanders, 2011, The Journal of clinical investigation.

In situ expression of tumor antigens by messenger RNA-electroporated dendritic cells in lymph nodes of melanoma patients.

W. Oyen, C. Figdor, C. Punt, 2009, Cancer research.

Maturation of monocyte-derived dendritic cells with Toll-like receptor 3 and 7/8 ligands combined with prostaglandin E2 results in high interleukin-12 production and cell migration

C. Figdor, C. Punt, G. Adema, 2008, Cancer Immunology, Immunotherapy.

Characterization of the replication region of the Bacillus subtilis plasmid pLS20: a novel type of replicon.

S. Bron, G. Venema, G. Venemâ, 1995, Nucleic acids research.

Genetic vaccination against the melanocyte lineage-specific antigen gp100 induces cytotoxic T lymphocyte-mediated tumor protection.

C. Figdor, G. Adema, M. Schreurs, 1998, Cancer research.

Immunogenicity of dendritic cells pulsed with CEA peptide or transfected with CEA mRNA for vaccination of colorectal cancer patients.

C. Figdor, C. Punt, G. Adema, 2010, Anticancer research.

Dendritic cells break tolerance and induce protective immunity against a melanocyte differentiation antigen in an autologous melanoma model.

R. Offringa, C. Figdor, G. Adema, 2000, Cancer research.

A pilot study on the immunogenicity of dendritic cell vaccination during adjuvant oxaliplatin/capecitabine chemotherapy in colon cancer patients

C. Figdor, C. Punt, G. Adema, 2010, British Journal of Cancer.

Protein phosphorylation and tyrosine kinase activity in medullary thyroid carcinomas of the rat.

G. Staal, G. Rijksen, A. D. de Boer, 1987, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.

Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice.

C. Figdor, C. Punt, J. Kaanders, 2011, The Journal of clinical investigation.

Maturation of monocyte-derived dendritic cells with Toll-like receptor 3 and 7/8 ligands combined with prostaglandin E2 results in high interleukin-12 production and cell migration

C. Figdor, C. Punt, G. Adema, 2008, Cancer Immunology, Immunotherapy.

Adjuvant dendritic cell therapy in stage IIIB/C melanoma: the MIND-DC randomized phase III trial

Inge M. N. Wortel, J. Bonenkamp, W. Gerritsen, 2024, Nature communications.